Stockreport

Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating [Yahoo! Finance]

Ocugen, Inc.  (OCGN) 
PDF initiated with an Outperform rating and a $10 price target at Oppenheimer. The firm noted that they find the company to be an upcoming leader in gene therapy for blind [Read more]